Clinical Data Spyre deprioritises arthritis drug after Phase 2 results PharmaphorumSpyre Therapeutics' hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.Immunology & InflammationRead full story pharminent August 26, 2026 (Last updated: August 26, 2026) Pharmaphorum Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road. Immunology & Inflammation Read full story Post navigation Previous: Jazz secures FDA approval for Ziihera in advanced HER2+ GEA Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future pharminent August 20, 2026
